“INDISCRIMINATE USE OF GLP-1 ANALOGUES, SUCH AS SEMAGLUTIDE (OZEMPIC®), FOR AESTHETIC PURPOSES AND MULTIDISCIPLINARY ACTION IN CARE AND RISK PREVENTION” (2025) Editora Impacto Científico, pp. 342–356. Available at: https://periodicos.newsciencepubl.com/editoraimpacto/article/view/9073 (Accessed: 20 February 2026).